Napp Pharmaceuticals Limited
Cambridge Science Park
Milton Road
Cambridge
CB4 0AB

July 17th 2015

Attn. Lori Farrar.

Centre for Health Technology Evaluation
National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Dear Lori

Further to your recent email please find the information requested by NICE relating to the tender prices for Remsima®. We wish to inform The Committee that Remsima is available to the NHS at tender prices up to [redacted] below the Remicade list price (£419.62) as already stated in our response to the ACD.

You have requested a price range and we are able to supply the following information, however is COMMERCIAL-IN-CONFIDENCE and should not be shared with other manufacturers.

The tender price range available to the NHS is between [redacted] and [redacted] per 100mg vial.

Given that The Committee's recommendation in the ACD is to recommend infliximab at the higher NHS list prices for Remicade (£419.62 per 100mg vial) and Remsima (£377.66 per 100mg vial) we hope that this new information will only strengthen the recommendation and make this valuable medicine more available to people with rheumatoid arthritis.

Should you have any further questions please contact me directly.

Yours sincerely

[redacted]

[redacted]

Public Affairs Manager